<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241109195416&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241109195416&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 10 Nov 2024 00:54:17 +0000</lastbuilddate>
<pubDate>Thu, 07 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Our revered and mysterious heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39506132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 6. doi: 10.1038/s41569-024-01096-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39506132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39506132</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01096-w>10.1038/s41569-024-01096-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39506132</guid>
<pubDate>Thu, 07 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Philip Kilner</dc:creator>
<dc:date>2024-11-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Our revered and mysterious heart</dc:title>
<dc:identifier>pmid:39506132</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01096-w</dc:identifier>
</item>
<item>
<title>Reply: Understanding Disparities in Coronary Artery Bypass Surgery Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e297. doi: 10.1016/j.jacc.2024.08.073.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505426</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.073>10.1016/j.jacc.2024.08.073</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505426</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Understanding Disparities in Coronary Artery Bypass Surgery Outcomes</dc:title>
<dc:identifier>pmid:39505426</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.073</dc:identifier>
</item>
<item>
<title>Advancing Women's CABG Outcomes: Broader Research and Community Needs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505425/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e295. doi: 10.1016/j.jacc.2024.07.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505425/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505425</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.052>10.1016/j.jacc.2024.07.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505425</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuli Guo</dc:creator>
<dc:creator>Ruirui Hou</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advancing Women's CABG Outcomes: Broader Research and Community Needs</dc:title>
<dc:identifier>pmid:39505425</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.052</dc:identifier>
</item>
<item>
<title>Vive la Différence: Addressing Graft Failure in Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505424/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e293-e294. doi: 10.1016/j.jacc.2024.07.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505424/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505424</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.047>10.1016/j.jacc.2024.07.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505424</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Xuan Jiang</dc:creator>
<dc:creator>Tianxiang Gu</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Vive la Différence: Addressing Graft Failure in Women</dc:title>
<dc:identifier>pmid:39505424</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.047</dc:identifier>
</item>
<item>
<title>Reply: The Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e291. doi: 10.1016/j.jacc.2024.08.072.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505423</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.072>10.1016/j.jacc.2024.08.072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505423</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Julian Gillmore</dc:creator>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Scott Solomon</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy</dc:title>
<dc:identifier>pmid:39505423</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.072</dc:identifier>
</item>
<item>
<title>The Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e289-e290. doi: 10.1016/j.jacc.2024.07.050.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505422</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.050>10.1016/j.jacc.2024.07.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505422</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Kuan-Yu Chi</dc:creator>
<dc:creator>Cesia Gallegos-Kattán</dc:creator>
<dc:creator>Nikhil V Sikand</dc:creator>
<dc:creator>Marc D Samsky</dc:creator>
<dc:creator>Michael G Nanna</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Impact of Socioeconomic Status and Diagnostic Timeline on Clinical Outcomes in ATTR Cardiomyopathy</dc:title>
<dc:identifier>pmid:39505422</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.050</dc:identifier>
</item>
<item>
<title>REPLY: To Pretreat or Not to Pretreat: That Is the Question</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e287. doi: 10.1016/j.jacc.2024.07.048.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505421</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.048>10.1016/j.jacc.2024.07.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505421</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Manuel Almendro-Delia</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: To Pretreat or Not to Pretreat: That Is the Question</dc:title>
<dc:identifier>pmid:39505421</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.048</dc:identifier>
</item>
<item>
<title>To Pretreat or Not to Pretreat: That Is the Question</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505420/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e285. doi: 10.1016/j.jacc.2024.07.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505420/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505420</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.049>10.1016/j.jacc.2024.07.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505420</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ali Dahhan</dc:creator>
<dc:creator>Mohammad Bilal Memon</dc:creator>
<dc:creator>Zachariah Zaaza</dc:creator>
<dc:creator>Ian Jennings</dc:creator>
<dc:creator>Hanan Gruhonjic</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>To Pretreat or Not to Pretreat: That Is the Question</dc:title>
<dc:identifier>pmid:39505420</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.049</dc:identifier>
</item>
<item>
<title>REPLY: Addressing the Gender Gap in Academic Authorship: Corrective Measures Must Not Be Delayed</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505419/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e283. doi: 10.1016/j.jacc.2024.08.074.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505419/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505419</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.074>10.1016/j.jacc.2024.08.074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505419</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ridhima Goel</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Addressing the Gender Gap in Academic Authorship: Corrective Measures Must Not Be Delayed</dc:title>
<dc:identifier>pmid:39505419</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.074</dc:identifier>
</item>
<item>
<title>Gender Diversity: Will Mandates Be the Best Way to Go?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e281. doi: 10.1016/j.jacc.2024.07.051.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505418</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.051>10.1016/j.jacc.2024.07.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505418</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Merle Myerson</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Gender Diversity: Will Mandates Be the Best Way to Go?</dc:title>
<dc:identifier>pmid:39505418</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.051</dc:identifier>
</item>
<item>
<title>Gender Disparities in Cardiovascular Literature: Expanding the Scope and Solutions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e279. doi: 10.1016/j.jacc.2024.07.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505417</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.053>10.1016/j.jacc.2024.07.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505417</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ruirui Hou</dc:creator>
<dc:creator>Jian Ren</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Gender Disparities in Cardiovascular Literature: Expanding the Scope and Solutions</dc:title>
<dc:identifier>pmid:39505417</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.053</dc:identifier>
</item>
<item>
<title>REPLY: Let Us Focus on Angina Mechanisms in Many, Not Just Typical Symptoms in a Few</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505416/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e277. doi: 10.1016/j.jacc.2024.08.075.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505416/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505416</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.075>10.1016/j.jacc.2024.08.075</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505416</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Christopher A Rajkumar</dc:creator>
<dc:creator>Rasha K Al-Lamee</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Let Us Focus on Angina Mechanisms in Many, Not Just Typical Symptoms in a Few</dc:title>
<dc:identifier>pmid:39505416</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.075</dc:identifier>
</item>
<item>
<title>Let Us Focus on Angina Mechanisms in Many, Not Just Typical Symptoms in a Few</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):e275. doi: 10.1016/j.jacc.2024.05.085.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505415</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.085>10.1016/j.jacc.2024.05.085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505415</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Christiaan J M Vrints</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Let Us Focus on Angina Mechanisms in Many, Not Just Typical Symptoms in a Few</dc:title>
<dc:identifier>pmid:39505415</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.085</dc:identifier>
</item>
<item>
<title>A Guide to Implementation Science for Phase 3 Clinical Trialists: Designing Trials for Evidence Uptake</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>The delayed and modest uptake of evidence-based treatments following cardiovascular clinical trials highlights the need for greater attention to implementation early in the development and testing of treatments. However, implementation science is not well understood and is often an afterthought following phase 3 trials. In this review, we describe the goals, frameworks, and methods of implementation science, along with common multilevel barriers and facilitators of implementation. We propose...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):2063-2072. doi: 10.1016/j.jacc.2024.08.068.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The delayed and modest uptake of evidence-based treatments following cardiovascular clinical trials highlights the need for greater attention to implementation early in the development and testing of treatments. However, implementation science is not well understood and is often an afterthought following phase 3 trials. In this review, we describe the goals, frameworks, and methods of implementation science, along with common multilevel barriers and facilitators of implementation. We propose that some of the approaches used for implementation well after a trial has ended can be incorporated into the design of phase 3 trials to foster early post-trial implementation. Approaches include, but are not limited to, engaging broad stakeholders including patients, clinicians, and decision-makers in trial advisory boards; using less restrictive eligibility criteria that ensure both internal validity and generalizability; having trial protocols reviewed by regulators; integrating trial execution with the health care system; evaluating and addressing barriers and facilitators to deployment of the intervention; and undertaking cost-effectiveness and cost utility analyses across jurisdictions. We provide case examples to highlight concepts and to guide end-of-trial implementation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505414</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.068>10.1016/j.jacc.2024.08.068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505414</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:creator>Laura Desveaux</dc:creator>
<dc:creator>Tracy Finch</dc:creator>
<dc:creator>Cara C Lewis</dc:creator>
<dc:creator>George A Mensah</dc:creator>
<dc:creator>Yves Rosenberg</dc:creator>
<dc:creator>Kavita Singh</dc:creator>
<dc:creator>Francois Venter</dc:creator>
<dc:creator>Bryan J Weiner</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Guide to Implementation Science for Phase 3 Clinical Trialists: Designing Trials for Evidence Uptake</dc:title>
<dc:identifier>pmid:39505414</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.068</dc:identifier>
</item>
<item>
<title>Artificial Intelligence in Cardiovascular Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial's life cycle, including designing the trial, identifying eligible patients, obtaining informed consent,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):2051-2062. doi: 10.1016/j.jacc.2024.08.069.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial's life cycle, including designing the trial, identifying eligible patients, obtaining informed consent, ascertaining physiological and clinical event outcomes, interpreting imaging, and analyzing or disseminating the results. Nevertheless, AI poses risks, including generating inaccurate results, amplifying biases against underrepresented groups, and violating patient privacy. Medical journals and regulators are developing new frameworks to evaluate AI research tools and the data they generate. Given the high-stakes role of randomized trials in medical decision making, AI must be integrated carefully and transparently to protect the validity of trial results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505413</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.069>10.1016/j.jacc.2024.08.069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505413</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Jessilyn Dunn</dc:creator>
<dc:creator>G Michael Felker</dc:creator>
<dc:creator>Sneha S Jain</dc:creator>
<dc:creator>Christopher J Lindsell</dc:creator>
<dc:creator>Matthew Mace</dc:creator>
<dc:creator>Trejeeve Martyn</dc:creator>
<dc:creator>Rashmee U Shah</dc:creator>
<dc:creator>Geoffrey H Tison</dc:creator>
<dc:creator>Tala Fakhouri</dc:creator>
<dc:creator>Mitchell A Psotka</dc:creator>
<dc:creator>Harlan Krumholz</dc:creator>
<dc:creator>Mona Fiuzat</dc:creator>
<dc:creator>Christopher M O'Connor</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Heart Failure Collaboratory</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Artificial Intelligence in Cardiovascular Clinical Trials</dc:title>
<dc:identifier>pmid:39505413</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.069</dc:identifier>
</item>
<item>
<title>Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39505412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Recaticimab as add-on to stable statin therapy significantly decreased LDL-C levels at week 24 and sustained the decreases through week 48, providing a novel therapeutic alternative with a dosing interval of up to every 12 weeks in patients with nonfamilial hypercholesterolemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 12;84(20):2037-2047. doi: 10.1016/j.jacc.2024.09.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Currently available antiproprotein convertase subtilisin/kexin type 9 monoclonal antibodies can effectively decrease low-density lipoprotein cholesterol (LDL-C) levels, but require frequent dosing. Recaticimab is a novel humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9. In a phase 1b/2 trial, recaticimab as add-on to stable statins showed robust LDL-C reduction with a dosing interval up to every 12 weeks (Q12W) in patients with hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: REMAIN-2 (REcaticiMab Add-on therapy In patients with Nonfamilial hypercholesterolemia) aimed to assess the efficacy and safety of 48-week treatment with recaticimab as add-on therapy to statins in nonfamilial hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: REMAIN-2 was a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. During the run-in period, patients received stable moderate or high-intensity statin, with or without cholesterol absorption inhibitors (ezetimibe) or fenofibrate, for ≥4 weeks. Patients with an LDL-C of ≥1.8 mmol/L (if with atherosclerotic cardiovascular disease [ASCVD]) or ≥2.6 mmol/L (if without ASCVD) were then randomized (2:2:2:1:1:1) to receive recaticimab 150 mg every 4 weeks (Q4W), 300 mg every 8 weeks (Q8W), or 450 mg Q12W, or matching placebo injections (Q4W, Q8W, or Q12W) for 48 weeks. The primary efficacy endpoint was percentage change from baseline to week 24 in LDL-C level.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 689 randomly assigned patients received treatment (mean age, 55.8 years; male, 64.4%; ASCVD history, 69.5%; concomitant ezetimibe, 11.2%; mean baseline LDL-C, 2.8 mmol/L). Percentage change in LDL-C from baseline to week 24 was significantly more pronounced with recaticimab vs placebo (P &lt; 0.0001), with least-squares mean differences of -62.2% (95% CI: -67.0% to -57.4%), -59.7% (95% CI: -65.0% to -54.4%), and -53.4% (95% CI: -58.7% to -48.2%) for the 150 mg Q4W, 300 mg Q8W, and 450 mg Q12W regimens, respectively. The decreases in LDL-C with recaticimab were maintained through week 48. Secondary lipid variables, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) also favored the recaticimab groups. During the treatment period, the incidence of treatment-related adverse events (28.5% vs 26.6%) and serious treatment-related adverse events (0.4% vs 0.4%) was similarly low in both the recaticimab and placebo groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Recaticimab as add-on to stable statin therapy significantly decreased LDL-C levels at week 24 and sustained the decreases through week 48, providing a novel therapeutic alternative with a dosing interval of up to every 12 weeks in patients with nonfamilial hypercholesterolemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39505412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39505412</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.012>10.1016/j.jacc.2024.09.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39505412</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yihong Sun</dc:creator>
<dc:creator>Qiang Lv</dc:creator>
<dc:creator>Yuhan Guo</dc:creator>
<dc:creator>Zhifang Wang</dc:creator>
<dc:creator>Rongjie Huang</dc:creator>
<dc:creator>Xiaohong Gao</dc:creator>
<dc:creator>Yajun Han</dc:creator>
<dc:creator>Zhuhua Yao</dc:creator>
<dc:creator>Mingqi Zheng</dc:creator>
<dc:creator>Suxin Luo</dc:creator>
<dc:creator>Yue Li</dc:creator>
<dc:creator>Xiang Gu</dc:creator>
<dc:creator>Yumin Zhang</dc:creator>
<dc:creator>Junkui Wang</dc:creator>
<dc:creator>Lang Hong</dc:creator>
<dc:creator>Xueping Ma</dc:creator>
<dc:creator>Guohai Su</dc:creator>
<dc:creator>Jianlong Sheng</dc:creator>
<dc:creator>Chunlin Lai</dc:creator>
<dc:creator>Aidong Shen</dc:creator>
<dc:creator>Mian Wang</dc:creator>
<dc:creator>WeiHua Zhang</dc:creator>
<dc:creator>Shaorong Wu</dc:creator>
<dc:creator>Zeqi Zheng</dc:creator>
<dc:creator>Juxiang Li</dc:creator>
<dc:creator>Tingyan Zhong</dc:creator>
<dc:creator>Ying Wang</dc:creator>
<dc:creator>Liu He</dc:creator>
<dc:creator>Xin Du</dc:creator>
<dc:creator>Chang-Sheng Ma</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial</dc:title>
<dc:identifier>pmid:39505412</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.012</dc:identifier>
</item>
<item>
<title>Organ-specific electrophile responsivity mapping in live C. elegans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504959/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>Proximity labeling technologies are limited to indexing localized protein residents. Such data-although valuable-cannot inform on small-molecule responsivity of local residents. We here bridge this gap by demonstrating in live C. elegans how electrophile-sensing propensity in specific organs can be quantitatively mapped and ranked. Using this method, >;70% of tissue-specific responders exhibit electrophile responsivity, independent of tissue-specific abundance. One responder, cyp-33e1-for which...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 2:S0092-8674(24)01190-5. doi: 10.1016/j.cell.2024.10.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Proximity labeling technologies are limited to indexing localized protein residents. Such data-although valuable-cannot inform on small-molecule responsivity of local residents. We here bridge this gap by demonstrating in live C. elegans how electrophile-sensing propensity in specific organs can be quantitatively mapped and ranked. Using this method, >;70% of tissue-specific responders exhibit electrophile responsivity, independent of tissue-specific abundance. One responder, cyp-33e1-for which both human and worm orthologs are electrophile responsive-marshals stress-dependent gut functions, despite manifesting uniform abundance across all tissues studied. Cyp-33e1's localized electrophile responsivity operates site specifically, triggering multifaceted responses: electrophile sensing through the catalytic-site cysteine results in partitioning between enzyme inhibition and localized production of a critical metabolite that governs global lipid availability, whereas rapid dual-cysteine site-specific sensing modulates gut homeostasis. Beyond pinpointing chemical actionability within local proteomes, organ-specific electrophile responsivity mapping illuminates otherwise intractable locale-specific metabolite signaling and stress response programs influencing organ-specific decision-making.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504959/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39504959</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.014>10.1016/j.cell.2024.10.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504959</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jinmin Liu</dc:creator>
<dc:creator>Amogh Kulkarni</dc:creator>
<dc:creator>Yong-Qi Gao</dc:creator>
<dc:creator>Daniel A Urul</dc:creator>
<dc:creator>Romain Hamelin</dc:creator>
<dc:creator>Balázs Á Novotny</dc:creator>
<dc:creator>Marcus J C Long</dc:creator>
<dc:creator>Yimon Aye</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Organ-specific electrophile responsivity mapping in live C. elegans</dc:title>
<dc:identifier>pmid:39504959</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.014</dc:identifier>
</item>
<item>
<title>Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504958/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>Ubiquitin-dependent proteolysis regulates diverse cellular functions with high substrate specificity, which hinges on the ability of ubiquitin E3 ligases to decode the targets' degradation signals, i.e., degrons. Here, we show that BACH1, a transcription repressor of antioxidant response genes, features two distinct unconventional degrons encrypted in the quaternary structure of its homodimeric BTB domain. These two degrons are both functionalized by oxidative stress and are deciphered by two...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 30:S0092-8674(24)01188-7. doi: 10.1016/j.cell.2024.10.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ubiquitin-dependent proteolysis regulates diverse cellular functions with high substrate specificity, which hinges on the ability of ubiquitin E3 ligases to decode the targets' degradation signals, i.e., degrons. Here, we show that BACH1, a transcription repressor of antioxidant response genes, features two distinct unconventional degrons encrypted in the quaternary structure of its homodimeric BTB domain. These two degrons are both functionalized by oxidative stress and are deciphered by two complementary E3s. FBXO22 recognizes a degron constructed by the BACH1 BTB domain dimer interface, which is unmasked from transcriptional co-repressors after oxidative stress releases BACH1 from chromatin. When this degron is impaired by oxidation, a second BACH1 degron manifested by its destabilized BTB dimer is probed by a pair of FBXL17 proteins that remodels the substrate into E3-bound monomers for ubiquitination. Our findings highlight the multidimensionality of protein degradation signals and the functional complementarity of different ubiquitin ligases targeting the same substrate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504958/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39504958</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.012>10.1016/j.cell.2024.10.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504958</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Shiyun Cao</dc:creator>
<dc:creator>Sheena Faye Garcia</dc:creator>
<dc:creator>Huigang Shi</dc:creator>
<dc:creator>Ellie I James</dc:creator>
<dc:creator>Yuki Kito</dc:creator>
<dc:creator>Hui Shi</dc:creator>
<dc:creator>Haibin Mao</dc:creator>
<dc:creator>Sharon Kaisari</dc:creator>
<dc:creator>Gergely Rona</dc:creator>
<dc:creator>Sophia Deng</dc:creator>
<dc:creator>Hailey V Goldberg</dc:creator>
<dc:creator>Jackeline Ponce</dc:creator>
<dc:creator>Beatrix Ueberheide</dc:creator>
<dc:creator>Luca Lignitto</dc:creator>
<dc:creator>Miklos Guttman</dc:creator>
<dc:creator>Michele Pagano</dc:creator>
<dc:creator>Ning Zheng</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress</dc:title>
<dc:identifier>pmid:39504958</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.012</dc:identifier>
</item>
<item>
<title>Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504957/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>Although immunotherapy has revolutionized cancer treatment, its efficacy is affected by multiple factors, particularly those derived from the complexity and heterogeneity of the tumor-immune microenvironment (TIME). Strategies that simultaneously and synergistically engage multiple immune cells in TIME remain highly desirable but challenging. Herein, we report a multimodal and programmable platform that enables the integration of multiple therapeutic modules into single agents for tumor-targeted...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 2:S0092-8674(24)01198-X. doi: 10.1016/j.cell.2024.10.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Although immunotherapy has revolutionized cancer treatment, its efficacy is affected by multiple factors, particularly those derived from the complexity and heterogeneity of the tumor-immune microenvironment (TIME). Strategies that simultaneously and synergistically engage multiple immune cells in TIME remain highly desirable but challenging. Herein, we report a multimodal and programmable platform that enables the integration of multiple therapeutic modules into single agents for tumor-targeted co-engagement of multiple immune cells within TIME. We developed the triple orthogonal linker (T-Linker) technology to integrate various therapeutic small molecules and biomolecules as multimodal targeting chimeras (Multi-TACs). The EGFR-CD3-PDL1 Multi-TAC facilitated T-dendritic cell co-engagement to target solid tumors with excellent efficacy, as demonstrated in vitro, in several humanized mouse models and in patient-derived tumor models. Furthermore, Multi-TACs were constructed to coordinate T cells with other immune cell types. The highly modular and programmable feature of our Multi-TACs may find broad applications in immunotherapy and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504957/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39504957</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.016>10.1016/j.cell.2024.10.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504957</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Feng Lin</dc:creator>
<dc:creator>Shenyi Yin</dc:creator>
<dc:creator>Zijian Zhang</dc:creator>
<dc:creator>Ying Yu</dc:creator>
<dc:creator>Haoming Fang</dc:creator>
<dc:creator>Zhen Liang</dc:creator>
<dc:creator>Rujie Zhu</dc:creator>
<dc:creator>Haitao Zhou</dc:creator>
<dc:creator>Jianjie Li</dc:creator>
<dc:creator>Kunxia Cao</dc:creator>
<dc:creator>Weiming Guo</dc:creator>
<dc:creator>Shan Qin</dc:creator>
<dc:creator>Yuxuan Zhang</dc:creator>
<dc:creator>Chenghao Lu</dc:creator>
<dc:creator>Han Li</dc:creator>
<dc:creator>Shibo Liu</dc:creator>
<dc:creator>Heng Zhang</dc:creator>
<dc:creator>Buqing Ye</dc:creator>
<dc:creator>Jian Lin</dc:creator>
<dc:creator>Yan Li</dc:creator>
<dc:creator>Xiaozheng Kang</dc:creator>
<dc:creator>Jianzhong Jeff Xi</dc:creator>
<dc:creator>Peng R Chen</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment</dc:title>
<dc:identifier>pmid:39504957</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.016</dc:identifier>
</item>
<item>
<title>Device-Measured 24-Hour Movement Behaviors and Blood Pressure: A 6-Part Compositional Individual Participant Data Analysis in the ProPASS Consortium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504653/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Study findings reiterate the importance of exercise for BP control, suggesting that small additional amounts of exercise are associated with lower BP in a free-living setting.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 6. doi: 10.1161/CIRCULATIONAHA.124.069820. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Blood pressure (BP)-lowering effects of structured exercise are well-established. Effects of 24-hour movement behaviors captured in free-living settings have received less attention. This cross-sectional study investigated associations between a 24-hour behavior composition comprising 6 parts (sleeping, sedentary behavior, standing, slow walking, fast walking, and combined exercise-like activity [eg, running and cycling]) and systolic BP (SBP) and diastolic BP (DBP).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from thigh-worn accelerometers and BP measurements were collected from 6 cohorts in the Prospective Physical Activity, Sitting and Sleep consortium (ProPASS) (n=14 761; mean±SD, 54.2±9.6 years). Individual participant analysis using compositional data analysis was conducted with adjustments for relevant harmonized covariates. Based on the average sample composition, reallocation plots examined estimated BP reductions through behavioral replacement; the theoretical benefits of optimal (ie, clinically meaningful improvement in SBP [2 mm Hg] or DBP [1 mm Hg]) and minimal (ie, 5-minute reallocation) behavioral replacements were identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The average 24-hour composition consisted of sleeping (7.13±1.19 hours), sedentary behavior (10.7±1.9 hours), standing (3.2±1.1 hours), slow walking (1.6±0.6 hours), fast walking (1.1±0.5 hours), and exercise-like activity (16.0±16.3 minutes). More time spent exercising or sleeping, relative to other behaviors, was associated with lower BP. An additional 5 minutes of exercise-like activity was associated with estimated reductions of -0.68 mm Hg (95% CI, -0.15, -1.21) SBP and -0.54 mm Hg (95% CI, -0.19, 0.89) DBP. Clinically meaningful improvements in SBP and DBP were estimated after 20 to 27 minutes and 10 to 15 minutes of reallocation of time in other behaviors into additional exercise. Although more time spent being sedentary was adversely associated with SBP and DBP, there was minimal impact of standing or walking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Study findings reiterate the importance of exercise for BP control, suggesting that small additional amounts of exercise are associated with lower BP in a free-living setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504653/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39504653</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069820>10.1161/CIRCULATIONAHA.124.069820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504653</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Joanna M Blodgett</dc:creator>
<dc:creator>Matthew N Ahmadi</dc:creator>
<dc:creator>Andrew J Atkin</dc:creator>
<dc:creator>Richard M Pulsford</dc:creator>
<dc:creator>Vegar Rangul</dc:creator>
<dc:creator>Sebastien Chastin</dc:creator>
<dc:creator>Hsiu-Wen Chan</dc:creator>
<dc:creator>Kristin Suorsa</dc:creator>
<dc:creator>Esmée A Bakker</dc:creator>
<dc:creator>Nidhi Gupta</dc:creator>
<dc:creator>Pasan Hettiarachchi</dc:creator>
<dc:creator>Peter J Johansson</dc:creator>
<dc:creator>Lauren B Sherar</dc:creator>
<dc:creator>Borja Del Pozo Cruz</dc:creator>
<dc:creator>Nicholas Koemel</dc:creator>
<dc:creator>Gita D Mishra</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Sari Stenholm</dc:creator>
<dc:creator>Alun D Hughes</dc:creator>
<dc:creator>Armando Teixeira-Pinto</dc:creator>
<dc:creator>Ulf Ekelund</dc:creator>
<dc:creator>I-Min Lee</dc:creator>
<dc:creator>Andreas Holtermann</dc:creator>
<dc:creator>Annemarie Koster</dc:creator>
<dc:creator>Emmanuel Stamatakis</dc:creator>
<dc:creator>Mark Hamer</dc:creator>
<dc:creator>ProPASS Collaboration</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Device-Measured 24-Hour Movement Behaviors and Blood Pressure: A 6-Part Compositional Individual Participant Data Analysis in the ProPASS Consortium</dc:title>
<dc:identifier>pmid:39504653</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069820</dc:identifier>
</item>
<item>
<title>The ESC Textbook of Heart Failure: breaking the new educational frontier</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39504565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241109195416&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 6:ehad897. doi: 10.1093/eurheartj/ehad897. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39504565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241109195416&v=2.18.0.post9+e462414">39504565</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad897>10.1093/eurheartj/ehad897</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39504565</guid>
<pubDate>Wed, 06 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Petar M Seferovic</dc:creator>
<dc:creator>Andrew J S Coats</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:date>2024-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Textbook of Heart Failure: breaking the new educational frontier</dc:title>
<dc:identifier>pmid:39504565</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad897</dc:identifier>
</item>





























</channel>
</rss>